To evaluate the therapeutic effect of Mongolian traditional prescriptions on patients with chronic obstructive pulmonary disease (COPD), a total of 153 COPD patients at stable stage were recruited, among which 94 patients were treated with budesonide, formoterol or indacaterol (western medicine group), and 59 patients were given additional Agari, Zandan-20, Qingfeirunze pill, etc. (Mongolian medicine group). After three months treatment, there was no significant difference in the pulmonary function indexes or six-minute walk test (6MWT) results between Mongolian and western medicine groups. There were significant differences in symptom score of Saint George's respiratory questionnaire (SGRQ) between the two groups (Adjusted P= 0.021). Compared with the baseline, the chronic obstructive pulmonary disease assessment test (CAT) score of the Mongolian medicine group decreased by 6 points, which was significantly higher than that of the western medicine group (Adjusted P< 0.001). For the CAT score, the proportions of patients decreased by 2 points or more, and the ratio of treated patients with lower or constant CAT score in the Mongolian medicine group were significantly higher than those in the western medicine group (P_{△CAT≤-2=0.001}, corrected P_{decreased/fixed} number=0.035). The disease impact score of SQGR decreased by 11.19 points in the Mongolian medicine group and 6.98 points in the western medicine group. The score of the Mongolian medicine group was significantly higher than that in the western medicine group (P=0.014). It was confirmed that the Mongolian medicine combined prescription can significantly improve respiratory symptoms, elevating the cardiopulmonary function.

chronic obstructive pulmonary disease (COPD)  /  Mongolian medicine  /  additional Agari  /  Zandan-20  /  Qingfeirunze pill  /  six-minute walk test  /  pulmonary function  /  respiratory scale